ECHO for Diabetes and Multiple Chronic Conditions Study

Part of paid clinical trials in Santa Fe, New Mexico.

Sponsor
University of New Mexico
Study ID
NCT06451458
Status
Enrolling By Invitation

Conditions

  • Chronic Disease
  • Diabetes Mellitus

Eligibility Criteria

Sex
ALL
Age
18 Years - 89 Years
Healthy Volunteers
Not accepted

Interventions

  • ECHO program for DMMC — BEHAVIORAL
    For the intervention, an 18-month ECHO program of weekly videoconference sessions will mentor healthcare teams on complex care strategies for patients with DMMC, emphasizing evidence-based best practices related to common chronic conditions (e.g., diabetes, CKD, hypertension, hyperlipidemia and depression). Mentorship will be provided by a multidisciplinary team of experts including a patient representative, diabetes educator, endocrinologist, psychiatrist, a nephrologist/kidney disease and hypertension specialist, a clinical pharmacist, and a cardiology consultant. Each session will consist of a didactic presentation, de-identified patient case presentations, and questions and discussion.
  • Usual care — BEHAVIORAL
    The comparator will consist of 10 PMS FQHC clinics with healthcare teams practicing usual care according to PMS standard practices during the 18 months of the intervention arm.

Study Details

Diabetes mellitus is a chronic condition that affects the body's ability to process sugar effectively, which over time can increase the risk of heart disease, high blood pressure, and kidney damage. Other chronic conditions include high cholesterol, obesity, and depression. Persons with diabetes mellitus and multiple chronic conditions (DMMC) face higher risks of losing physical or mental function, experiencing other chronic conditions, and death. Most of the residents of New Mexico (NM) belong to groups at risk for developing DMMC. Finding quality healthcare is a key factor, as NM also ranks among the largest, poorest, and most rural states. Primary care providers (PCPs) most often treat DMMC patients, but healthcare teams can lack confidence in managing these complex patients and struggle to keep up with recommended guidelines. This Project ECHO model (ECHO) for DMMC, a telehealth intervention for healthcare teams, can lead to lower blood sugar levels in DMMC patients being treated at NM primary care clinics. ECHO is a "telementoring" program that trains healthcare teams to provide specialized medical care at their local clinics. This is done by connecting healthcare teams with specialist mentors at academic medical centers through videoconferencing sessions. During ECHO program sessions, groups of healthcare teams hear lectures on key topics in DMMC care from experts, and then give presentations of anonymous patient cases by a healthcare teams for discussion and to receive recommendations. This clinical pragmatic trial aims to learn if the intervention will improve patient blood sugar levels in persons with DMMC who are being treated at selected health clinic sites throughout New Mexico. The study aims to answer: * Whether a 0.5% drop in HbA1c on average can be achieved in the group whose healthcare teams are receiving the ECHO intervention compared to the comparator group, whose providers will not receive the intervention. * Whether the rate of an individual's HbA1c was greater than 8.5% at the baseline will be reduced by 15% at the end of the intervention. Researchers will compare health data for patients empaneled to healthcare teams in the study and the usual care comparator group both before and after the intervention period to see whether the ECHO model has a positive influence on test results.

Key Dates

Start date
Oct 16, 2024
Status verified
Nov 2025
Primary completion
Sep 30, 2026
Completion
Jun 30, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ECHO Intervention
    10 FQHCs from the PMS health system will be randomized to the ECHO Intervention Arm. All healthcare team members in the intervention arm will attend ECHO program sessions, and the FQHCs are the primary subjects of the ECHO intervention. However, the investigators examine outcomes at both the level of the healthcare team and at the level of the patients who are empaneled to the healthcare team. Persons with DMMC cared for by the healthcare teams at the FQHC clinics are the patient population for this intervention.
  • Active Comparator: Comparator
    10 FQHCs from the PMS health system will be randomized to the comparator arm which is usual care. Persons with DMMC cared for by the healthcare teams at the FQHC clinics are the patient population for this comparator arm.

Primary Outcome Measure

HbA1c trajectory [ Time Frame: At least once every 6 months per Electric Health Record (EHR), during 12 months baseline prior to intervention, during 18 months intervention. ]

Locations (1)

FacilityCityStateZIPSite coordinators
Presbyterian Medical ServicesSanta FeNew Mexico87501-

Find similar trials in Santa Fe, NM

By research site
Presbyterian Medical Services· Santa Fe, NM

Related Studies